CF PharmaTech has secured $65m in a series D financing round led by SDIC. The Chinese respiratory drug developer plans to use the funds for the development of inhalation products.

Finnish biopharmaceutical company Aurealis Pharma has secured Sfr5.6m ($5.8m) in series A financing round led by Finnvera and Tekes.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

The company plans to use the funds to progress the development of its chronic wound treatment and cancer drugs AUP-16 and AUP-5550 into clinical safety and efficacy trials.

"aTyr Pharma plans to raise $45.8m through the private placement of its common stock shares and Class X Preferred Stock."

aTyr Pharma plans to raise $45.8m through the private placement of its common stock shares and Class X Preferred Stock.

Based in the US, aTyr is a biotherapeutics company focused on the development of physiocrine-based therapeutics.

The company plans to use the funds to progress the development of its therapeutic candidate programmes and for general corporate purposes.